IKBKE regulates renal cell carcinoma progression and sunitinib resistance through the RRM2-AKT pathw...
IKBKE regulates renal cell carcinoma progression and sunitinib resistance through the RRM2-AKT pathway
About this item
Full title
Author / Creator
Liu, Shiwei , Li, Junhong , Zhang, Junyu , Wan, Fangning , Hong, Zongyuan , Hong, Zhe and Dai, Bo
Publisher
Australia: Ivyspring International Publisher
Journal title
Language
English
Formats
Publication information
Publisher
Australia: Ivyspring International Publisher
Subjects
More information
Scope and Contents
Contents
Tyrosine kinase inhibitors (TKIs), such as sunitinib, have emerged as promising agents in renal cell carcinoma (RCC) treatment, particularly in patients at advanced/metastatic clinical stages. However, acquired resistance to sunitinib is common following prolonged clinical treatment in RCC. Increasing evidence has demonstrated a strong correlation...
Alternative Titles
Full title
IKBKE regulates renal cell carcinoma progression and sunitinib resistance through the RRM2-AKT pathway
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11628342
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11628342
Other Identifiers
ISSN
1449-2288
E-ISSN
1449-2288
DOI
10.7150/ijbs.102666
